Who are IMP Pioglitozone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pioglitazone Tablets, Rosiglitazone XR, Pioglitazone, Rosiglitazone, Pioglitazone rescue therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imp-pioglitozone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

IMP Pioglitozone — Competitive Intelligence Brief

IMP Pioglitozone (IMP Pioglitozone) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione (PPAR-γ agonist). Area: Diabetes.

marketed Thiazolidinedione (PPAR-γ agonist) PPAR-γ (Peroxisome proliferator-activated receptor gamma) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

IMP Pioglitozone (IMP Pioglitozone) — University of Nottingham. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IMP Pioglitozone TARGET	IMP Pioglitozone	University of Nottingham	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Pioglitazone Tablets	Pioglitazone Tablets	Peking Union Medical College Hospital	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Rosiglitazone XR	Rosiglitazone XR	GlaxoSmithKline	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Pioglitazone, Rosiglitazone	Pioglitazone, Rosiglitazone	Korea University Anam Hospital	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Pioglitazone rescue therapy	Pioglitazone rescue therapy	Merck Sharp & Dohme LLC	phase 3	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione (PPAR-γ agonist) class)

GlaxoSmithKline · 1 drug in this class
Korea University Anam Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
University of Nottingham · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMP Pioglitozone — Competitive Intelligence Brief. https://druglandscape.com/ci/imp-pioglitozone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab